Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, July 19, 2012

Migraine patch application resubmitted for FDA approval

I wonder if this could be useful to us, there are a number of nasal delivery systems. Could we attach nanoparticles and put the patch over our nose to provide a shortcut to the brain? Inquiring minds want to know.
http://medcitynews.com/2012/07/migraine-patch-application-resubmitted-for-fda-approval/
NuPathe (NASDAQ:PATH), a biopharmaceutical company, has resubmitted a new drug application for its migraine patch to the U.S. Food and Drug Administration after resolving issues raised in a complete response letter last year.
The Zelrix transdermal patch is designed to transmit sumatriptan via electrical charge through the skin in a drug-delivery method known as iontophoresis. The method, designed to speed up the delivery process, was chosen since one symptom migraine headache sufferers experience is nausea, which makes oral medication a challenge.
Jane Hollingsworth, NuPathe’s CEO, said she expects a six-month review by the FDA.

“With the additional data and enhancements made to the patch, we have submitted a strong application and have an even more attractive commercial opportunity designed to address the needs of the nearly half of migraine patients who frequently experience both headache pain and migraine-related nausea,” a company statement said.Among the Conshohocken, Pennsylvania company’s investors are Quaker BioVentures, which holds a 22 percent stake; Safeguard Scientifics (NYSE:SFE); Battelle Ventures; and GlaxoSmithKlein‘s (NYSE:GSK) venture capital arm, SROne.

Tags: , , ,


1 comment:

  1. Took me time to read all the comments, but I truly loved the article. It proved to be really useful to me and I am sure to all of the commenter here! It is usually good when you cannot only be informed, but additionally engaged! I am sure you had joy writing this article.

    kit de xenon

    ReplyDelete